603669.SH
灵康药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 5.39
−1.64%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−22.4x
Market Cap
CNY 3.84B
MomentumView details →
1D Return
−1.64%
YTD Return
+14.47%
RSI (14)
39.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−22.4x
Market Cap
CNY 3.84B
RSI (14)
39.2
MomentumView details →
1D Return
−1.64%
YTD Return
+14.47%
Similar companies
Latest newsMore news →
Lingkang Pharmaceutical reported its 2026 half-year results, with revenue of 257 million yuan, up 50.03% year-on-year, and net profit attributable to shareholders of 21.11 million yuan, turning from a loss to a profit.21d agoLingang Pharmaceutical announced its 2026 first-half results, reporting a net profit of 21.1127 million yuan, turning around from a loss in the prior year.21d agoLingang Pharmaceutical's subsidiary Lingang Pharma's product Huperzine A for injection (brand Ruilisu) was selected in a provincial alliance centralized procurement led by Henan Province, with a 2-year procurement cycle.24d ago